Meeting
2014 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.
Authors
Bertrand Tombal
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Bertrand Tombal , Michael Borre , Per Rathenborg , Patrick Werbrouck , Hendrik Van Poppel , Axel Heidenreich , Peter Iversen , Johan Braeckman , Jiri Heracek , Edwina Baskin-Bey , Taoufik Ouatas , Frank Perabo , De Phung , Matthew R. Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01302041
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 62)
DOI
10.1200/jco.2014.32.4_suppl.62
Abstract #
62
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
First Author: Bertrand F. Tombal
Poster
2024 ASCO Genitourinary Cancers Symposium
ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
First Author: Andrew Leonard Laccetti
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).
First Author: Bertrand F. Tombal
Poster
2018 Genitourinary Cancers Symposium
Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.
First Author: Glenn Bubley